Altimmune (ALT)

• Market cap: $532M
• 1 day: -0.39%
• 5 days: -5.56%
• 1 month: 38.59%
• 3 months: 27.5%
• 6 months: 33.16%
• Year to date: 45.3%
• 1 year: -26.62%
• 5 years: -64.29%
• 10 years: -98.92%
• Sector: Healthcare
• Industry: Biotechnology

About: Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Employees: 59